Gapping up
In reaction to earnings/guidance:
- AEHR +18.4% (issues upside guidance for Q1, raises FY22 guidance), PRGS +7.8% (also to acquire privately held Kemp for $258 mln), COST +0.6%
Other news:
- VTVT +24.3% (announces results from multiple ascending dose study evaluating HPP737 for psoriasis)
- CAPR +17.9% (reports final data from its Phase 2 HOPE-2 Trial)
- TMCI +9.9% (presents new ALIGN3D data)
- SRGA +3% (CFO/COO resigns)
- GDYN +2.4% (enters into strategic partnerships with Evinced to drive accessibility in mobile app development)
- AZN +2.3% (reports Phase III trial for Lynparza (olaparib) in combination with abiraterone)
Analyst comments:
- RRGB +2.6% (upgraded to Buy from Hold at Jefferies)
- BJRI +2.3% (upgraded to Buy from Hold at Jefferies)
- CHUY +2% (upgraded to Buy from Hold at Jefferies)
- PLAY +1.9% (upgraded to Buy from Hold at Jefferies)
- CAKE +1.3% (upgraded to Buy from Hold at Jefferies)
- ALV +0.9% (upgraded to Equal-Weight from Underweight at Morgan Stanley)